Logos Capital is a fundamental biotechnology-focused fund that seeks to combine in-house data analytics with scientific and clinical expertise to identify transformative therapies in healthcare.
Employees: 1-10
Investment Stage: Series B
Portfolio 58
| Date | Name | Website | Total Raised | Location |
| 07.08.2023 | Gracell Bi... | gracellbio.com | $250M | China, Jia... |
| 11.07.2023 | @Septerna_... | septerna.com | $290M | United Sta... |
| 17.10.2022 | Odyssey Th... | odysseytx.com | $487M | United Sta... |
| 27.08.2021 | Willow | onewillow.com | - | - |
| 17.08.2021 | Nuvalent | nuvalent.com | $187.23M | United Sta... |
| 17.08.2021 | Graphite B... | graphitebio.com | $195.75M | United Sta... |
| 17.08.2021 | Interius | interiusbio.com | $76M | United Sta... |
| 17.08.2021 | century_tx | centurytx.com | $410M | United Sta... |
| 17.08.2021 | Boundless ... | boundlessbio.com | $251.4M | United Sta... |
| 17.08.2021 | Ventyx Bio... | ventyxbio.com | $165M | United Sta... |
Show more
Mentions in press and media 5
| Date | Title | Description |
| 25.07.2024 | Canadian Startups Surge: Clio and Third Arc Bio Lead the Charge** ** | ** In the world of startups, the spotlight often shines brightest on Silicon Valley. Yet, this week, Canadian startups have taken center stage, proving that innovation knows no borders. Two companies, Clio and Third Arc Bio, have made headl... |
| 23.07.2024 | Third Arc Bio launches with $165M to address unmet needs in oncology and autoimmunity | The company was founded by executives from Johnson & Johnson Third Arc Bio is a company that says its on mission to deliver transformational therapies for solid tumors and inflammatory & immunology diseases through the use of multif... |
| 23.10.2023 | Which VCs are investing in rare diseases? | Firms include Chiesi Ventures, Frazier Healthcare Partners, OrbiMed, and Atlas Venture In the United States alone 25 million people suffer from rare disease, a number that jumps to 400 million people globally. While 1 in 10 people will suff... |
| 14.09.2021 | Vanqua Bio Launches with $85 Million Series B Financing and a Mission to Vanquish Neurodegenerative Diseases | – Novel drug-development approach combines advanced insights into critical neuronal cell pathways with cutting-edge assays to enable next-generation therapies – – Lead program targets Parkinson’s disease and all forms of Gaucher disease – C... |
| 09.01.2021 | Visen Pharmaceuticals Closes $150M Series B Financing | Visen Pharmaceuticals, a Shangai, China-based biotech company focused on developing and commercializing innovative endocrine drugs that address significant unmet needs for patients in Greater China, closed a $150m Series B financing. The ro... |